• Intellia Therapeutics recently reported additional positive results from its Phase 3 HAELO trial of gene-editing therapy lonvo-z for hereditary angioedema at the EAACI 2026 Congress in Istanbul, showing strong reductions in attack rates and high proportions of attack- and therapy-free patients.
• The company has also begun a rolling biologics license application with the FDA for lonvo-z, signaling that its first potential commercial gene-editing therapy may be moving closer to the market and could reshape expectations for Intellia’s pipeline and future business profile.
• We’ll now examine how lonvo-z’s strong Phase 3 data and rolling FDA submission could reshape Intellia’s investment narrative and risk profile.

Find 44 companies with promising cash flow potential yet trading below their fair value.

Intellia Therapeutics Investment Narrative Recap

To own Intellia today, you need to believe that one time CRISPR treatments like lonvo z can become real commercial products and support a broader pipeline. The HAELO Phase 3 data and rolling FDA submission keep lonvo z as the key near term catalyst, while execution and regulatory risk across a very concentrated late stage portfolio remain the biggest near term concerns.

The most relevant recent announcement here is Intellia’s decision to start a rolling BLA for lonvo z, backed by the strong HAELO data and expedited designations. Together, these steps frame lonvo z as the company’s potential first commercial gene editing therapy and a major test of whether Intellia can turn promising trial results into a viable, reimbursed product.

Yet alongside this upside, investors should be aware that concentrated dependence on just a couple of late stage programs means that any regulatory setback could...

Intellia Therapeutics' narrative projects $847.4 million revenue and $46.7 million earnings by 2029.

Uncover how Intellia Therapeutics' forecasts yield a $26.63 fair value, a 120% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were already assuming revenue could reach about US$6.0 billion and earnings US$1.9 billion by 2029, which is far more aggressive than the baseline view and may look different once the full implications of lonvo z’s new data and the highlighted payer and safety risks are clearer.

Explore 4 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.